# Demo Narrative and Interview Talk Track

## End-to-end story

A final diagnostic report arrives, is linked to the correct patient and encounter, assigned to the accountable clinician, reviewed with source-linked AI assistance, acknowledged, converted into a human-approved referral handoff, accepted by the receiving team and progressed to a confirmed next safe care step.

## Serious failure

An amended report arrives after acknowledgement. ContinuumOS invalidates the prior completion state, reopens review, alerts the accountable clinician and records the full trace.

## Safety decision segment

Use one hazard from `Sprints/Sprint_6_Prototype_Build_Testing_and_Controlled_Release/product_safety_hazard_and_control_register.csv` and explain:

1. the worst credible workflow effect, potential scope, immediacy and reversibility;
2. why the related guardrail is a product requirement rather than a disclaimer;
3. the prevention, detection, human owner and safe-recovery design;
4. the accepted operating cost, such as additional review, reconciliation or a less seamless failure state;
5. the executed test, defect and release evidence, if available; and
6. the residual uncertainty that the synthetic prototype cannot resolve.

Do not claim that the hazard was mitigated, that the product is safe or that the control is effective until the linked Sprint 6 evidence exists. Do not quantify harm, probability, guardrail cost or business benefit without an approved method and recorded data.

## Decision and alternatives

Explain why the case selected a bounded orchestration overlay instead of an EHR replacement, generic task tracker, broad integration platform or autonomous AI agent. Connect the choice to source-system authority, human decision rights, safe exception recovery, delivery focus and the opportunity cost of deferring wider scope.

Do not describe these approach comparisons as verified competitor weaknesses. Named-product comparisons belong only in the optional sourced Sprint 7 appendix.

## Evidence and lessons

Separate the talk track into:

1. decisions and hypotheses established before build;
2. observations recorded during Sprint 6 testing;
3. findings from structured Sprint 7 review or the synthetic pilot;
4. changes, deferrals or stop decisions linked to that evidence; and
5. limitations and the next evidence needed.

Do not populate findings, lessons or product improvements until their test, defect, reviewer or pilot references exist.

### Current pilot evidence

The pilot executed 20 controlled scenario runs against one approved synthetic tracer. The happy path and failure controls passed; four browser-observed actions showed feedback in 0.311–0.748 seconds. This demonstrates deterministic local prototype controls, not human workflow speed, operational performance, clinical safety or AI quality.

The evidence supports a deferred decision: no product change is claimed from the synthetic pilot alone. Structured reviewer feedback is the next evidence source before revising the product.

## Delivery limit

The prototype demo must be deliverable in under five minutes.
